BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS

1. (Previously presented) A compound of formula I



(I)

wherein

A is N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N; then Y must be CR_7;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_7 and R_{11} are each independently H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Original) The compound according to claim 1 wherein R_8 is an optionally substituted phenyl group.

B1

4. (Original) The compound according to claim 1 wherein R_2, R_3, R_4, R_5 and R_6 are H.

5. (Previously presented) The compound according to claim 1 wherein R_1 is H or a C_1-C_6alkyl or cycloheteroalkyl group each optionally substituted.

6. (Original) The compound according to claim 5 selected from the group consisting of:

1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-bromothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4,5-dichlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

methyl 4-[(4-piperazin-1-yl-1H-indol-1-yl)sulfonyl]phenyl ether;

4-piperazin-1-yl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(2-bromophenyl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indole;

4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(3-methoxybenzyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

B1 1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and

the pharmaceutically acceptable salts thereof.

7. (Currently amended) A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is selected from the group consisting essentially of: schizophrenia and depression~~; and a cognitive disorder~~ in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_7 and R_{11} are each independently H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Previously presented) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

B1 R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_7 and R_{11} are each independently H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is O or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

13. (Cancelled)

14. (Original) The composition according to claim 12 wherein R_8 is an optionally substituted phenyl group.

15. (Original) The composition according to claim 12 wherein R_2, R_3, R_4, R_5 and R_6 are H.

16. (Previously presented) The composition according to claim 12 wherein R_1 is H or a C_1-C_6alkyl or cycloheteroalkyl group each optionally substituted.

17. (Original) The composition according to claim 16 having a compound of formula I selected from the group consisting of:

1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-bromothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4,5-dichlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

methyl 4-[(4-piperazin-1-yl-1H-indol-1-yl)sulfonyl]phenyl ether;

4-piperazin-1-yl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(2-bromophenyl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indole;

4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(3-methoxybenzyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and

the pharmaceutically acceptable salts thereof.

18. (Previously presented) A method for the preparation of a compound of formula I.

B1



(I)

wherein

A is N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7;

R_1 is C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_7 and R_{11} are each independently H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond

said method which comprises reacting a compound of formula Ia



(Ia)

wherein A, X, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, m and n are as defined hereinabove for formula I with a compound R_1-Hal wherein R_1 is as defined hereinabove for formula I and Hal is Cl, Br or I.

19. (Currently amended) A compound of formula I



(I)

wherein

A is N;

X is CR_{11} ~~or N;~~

Y is ~~CR_7 or~~ N ~~with the provisos that when X is N, then Y must be CR_7 and at least one of X and Y must be N~~;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

~~R_7 and~~ R_{11} ~~are each independently~~ is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

20. (Previously presented) The compound according to claim 19 wherein R_8 is an optionally substituted phenyl group.

B1

21. (Previously presented) The compound according to claim 19 selected from the group consisting of:

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and

the pharmaceutically acceptable salts thereof.

22. (Currently amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11} ~~or N;~~

Y is ~~CR_7 or~~ N ~~with the provisos that when X is N, then Y must be CR_7 and at least one of X and Y must be N~~;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

~~R_7 and~~ R_{11} ~~are each independently~~ is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is O or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

23. (Previously presented) The composition according to claim 22 having a compound of formula I selected from the group consisting of:

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and

B1 the pharmaceutically acceptable salts thereof.